Background
It has become clear in recent years that drugs can lead to offtarget increases in blood pressure, and can do so via a variety of mechanisms of action. As Grossman and Messerli 2 observed, "Some agents cause either sodium retention or extracellular volume expansion, or activate directly or indirectly the sympathetic nervous system. Other substances act directly on arteriolar smooth muscle or do not have a defined mechanism of action. Some medications that usually lower BP may paradoxically increase BP, or an increase in pressure may be encountered after their discontinuation." Table 1 3,4 provides examples of off-target blood pressure effects seen in multiple drug classes. Because of this accumulating knowledge, in July 2012 the Cardiac Safety Research Consortium (CSRC) sponsored a Think Tank with the intent of moving toward consensus on how to most informatively collect and analyze blood pressure during clinical drug development to prospectively identify unacceptable cardiovascular risk and to evaluate the benefitrisk relationship. Discussions at that meeting were captured in a 2013 paper published in the American Heart Journal. 4 Now, several years later, FDA has released a draft guidance document addressing this issue. 1 As I write this Editorial, we are in the midst of a 60-day period in which comments and suggestions regarding the draft document can be submitted to FDA. After the close of this period, it is expected that FDA will take this feedback into account and that, at a point in the future, they will release a finalized Guidance for Industry. Also as I write, the CSRC is in the planning stages for a follow-up Think Tank on this topic after the close of the open comment period.
Topics Addressed in the Draft Guidance
Several topics addressed in the guidance are summarized here. Readers are encouraged to read the whole guidance.
Short-term Versus Chronic Use of a Drug
A sponsor's decision as to how to assess blood pressure during a premarketing clinical trial(s) depends upon whether the drug is intended for short-term or chronic use. If a drug indicated for short-term use has, at most, small effects on blood pressure, there will be little concern since the cardiovascular risk of small short-term elevations in blood pressure increases is not thought to be significant. However, large blood pressure increases are of concern even across a short period of a drug's use.
Concern is greater for a drug's effect on blood pressure when it will be used chronically. Sustained increases in blood pressure correlate with long-term increased risk of cardiovascular events, and increases in blood pressure as small as 2 to 3 mmHg would be expected to have such an effect. 1 Accordingly, sponsors should include a thorough blood pressure assessment as described in the guidance for drugs intended for chronic use. Ambulatory blood pressure monitoring (ABPM) is recommended for this assessment.
Ambulatory Blood Pressure Monitoring
Many biomarkers show a considerable degree of normal physiological variability, and this is particularly true for blood pressure. The measurement modality of ABPM 5 is therefore a powerful investigative tool in this context. As Pickering and colleagues 6 observed in the context of clinical practice, any clinical measurement of blood pressure may be regarded as a surrogate measure for the true blood pressure of the patient, which may be defined as the mean level over prolonged periods. ABPM has proved informative in the context of investigating the efficacy of antihypertensive agents, 7 and many authorities regard it as mandatory for the proper management of hypertension. [8] [9] [10] Additional references are provided. [11] [12] [13] [14] [15] [16] [17] In the context of premarketing assessment of a drug's effect on blood pressure, ABPM offers the precision and accuracy needed to detect relatively small but important changes in blood pressure. The guidance notes that ABPM devices, which can be programmed to collect measurements at specified times, provide a large number of blood pressure measurements throughout a 24-hour period, providing both a more precise assessment of average change and increased ability to describe ABPM is recommended for any clinical study designed to describe blood pressure effects over 24 hours. Measurements should be performed in the patient population for which the drug is being developed, either in a dedicated study or as part of a larger study already being conducted in this population.
Study Design for Drugs Intended for Chronic Use
Even though ABPM measurements are not influenced by investigator bias and provide precision, inclusion of a placebo group in the study is generally desirable. The study's Protocol should specify whether systolic (SBP), diastolic (DBP), or mean blood pressure will be evaluated. ABPM should be employed to measure pressure through the day, and should not be done before the drug has reached steady state.
If the drug increases blood pressure in the overall patient population, its sponsor should obtain additional information concerning its effects in subsets of the population who may experience larger effects, for example, patients with preexisting hypertension and patients with impaired renal function.
Regulatory Considerations
It is worth quoting part of this section:
The approached outlined in this guidance-identifying drugs that increase blood pressure and determining the size of the effectshould be factored into the overall benefit-risk assessment for the drug, recognizing that increasing blood pressure can be acceptable or can be managed satisfactorily in many circumstances. This assessment should include the consideration of any steps that could be taken to mitigate the risk of increased blood pressure, such as patient selection, pretreatment assessments, blood pressure monitoring in some or all patients, and planned use of blood pressurelowering treatments.
Encouragement for Sponsors to Seek Further Discussion with FDA
It should be noted here that the FDA encourages sponsors to seek further discussion with them on multiple issues addressed in the guidance.
A Recent Study Employing ABPM is of Note
A paper published last month in the journal Blood Pressure Monitoring by Weber and colleagues 18 is of note here. It discussed the employment of ABPM as part of a comprehensive blood pressure safety evaluation in patients with an overactive bladder (OAB) receiving solifenacin, mirabegron, or a combination of both compared with placebo. Solifenacin, an antimuscarinic agent, and mirabegron, a b 3 -adrenoceptor agonist, can each increase blood pressure (and heart rate) in a small percentage of patients. Thus, "The recent development of a combination of these two drugs created the need for a rigorous plan to monitor and analyze their hemodynamic effects when used in combination in the treatment of OAB." Along with office and home blood pressure measurements, ABPM was an important component of that rigorous plan.
A subset of 715 individuals in the overall participant population were analyzed in an ABPM sub-study. The double-blind treatment period was 12 weeks. At the end of week 4 and the end of treatment, mean 24-hour SBP and DBP obtained via ABPM showed no consistent increases from baseline for combination versus monotherapy groups, or for monotherapy groups versus placebo.
Concluding Comment
It will be very interesting to many of us involved with cardiovascular safety to see the final version of this guidance. I will update readers when it is released. J. Rick Turner, PhD, DSc, FASH, FACC, FESC, FCP Editor-in-Chief, Therapeutic Innovation & Regulatory Science
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